ReShape Lifesciences Inc. (NasdaqCM: RSLS) Loss Submission Form

Kuznicki Law is investigating the proposed merger of ReShape Lifesciences Inc. (the “Company”) (NasdaqCM: RSLS) and Vyome Therapeutics, Inc. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape’s actual net cash at closing compared to a target net cash amount of $5 million. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to ReShape shareholders.